165 related articles for article (PubMed ID: 27224851)
21. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
Tian Y; Deng YB; Huang YJ; Wang Y
Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
[TBL] [Abstract][Full Text] [Related]
22. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts.
Bleakley M; Heimfeld S; Loeb KR; Jones LA; Chaney C; Seropian S; Gooley TA; Sommermeyer F; Riddell SR; Shlomchik WD
J Clin Invest; 2015 Jul; 125(7):2677-89. PubMed ID: 26053664
[TBL] [Abstract][Full Text] [Related]
24. Emerging drugs for acute graft-versus-host disease.
Khaled Y; Reddy P; Krijanovski O
Expert Opin Emerg Drugs; 2009 Jun; 14(2):219-32. PubMed ID: 19519285
[TBL] [Abstract][Full Text] [Related]
25. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
26. Targeting the IL17 pathway for the prevention of graft-versus-host disease.
van der Waart AB; van der Velden WJ; Blijlevens NM; Dolstra H
Biol Blood Marrow Transplant; 2014 Jun; 20(6):752-9. PubMed ID: 24565991
[TBL] [Abstract][Full Text] [Related]
27. Ocular graft-versus-host disease: a review.
Shikari H; Antin JH; Dana R
Surv Ophthalmol; 2013; 58(3):233-51. PubMed ID: 23541042
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib.
Sun K; Welniak LA; Panoskaltsis-Mortari A; O'Shaughnessy MJ; Liu H; Barao I; Riordan W; Sitcheran R; Wysocki C; Serody JS; Blazar BR; Sayers TJ; Murphy WJ
Proc Natl Acad Sci U S A; 2004 May; 101(21):8120-5. PubMed ID: 15148407
[TBL] [Abstract][Full Text] [Related]
29. T-bet Promotes Acute Graft-versus-Host Disease by Regulating Recipient Hematopoietic Cells in Mice.
Fu J; Wu Y; Nguyen H; Heinrichs J; Schutt S; Liu Y; Liu C; Jin J; Anasetti C; Yu XZ
J Immunol; 2016 Apr; 196(7):3168-79. PubMed ID: 26903480
[TBL] [Abstract][Full Text] [Related]
30. Donor Cell Composition and Reactivity Predict Risk of Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
Sairafi D; Stikvoort A; Gertow J; Mattsson J; Uhlin M
J Immunol Res; 2016; 2016():5601204. PubMed ID: 27965986
[No Abstract] [Full Text] [Related]
31. Valproic Acid Ameliorates Graft-versus-Host Disease by Downregulating Th1 and Th17 Cells.
Long J; Chang L; Shen Y; Gao WH; Wu YN; Dou HB; Huang MM; Wang Y; Fang WY; Shan JH; Wang YY; Zhu J; Chen Z; Hu J
J Immunol; 2015 Aug; 195(4):1849-57. PubMed ID: 26179902
[TBL] [Abstract][Full Text] [Related]
32. The protection and therapy effects of bortezomib in murine acute graft-versus-host disease.
Li Z; Wu Q; Yan Z; Li D; Lu G; Mou W; Wu S; Pan X; Lu Q; Xu K
Transplant Proc; 2013; 45(6):2527-35. PubMed ID: 23953575
[TBL] [Abstract][Full Text] [Related]
33. Graft-versus-host disease: a complex long-term side effect of hematopoietic stem cell transplant.
Barton-Burke M; Dwinell DM; Kafkas L; Lavalley C; Sands H; Proctor C; Johnson E
Oncology (Williston Park); 2008 Oct; 22(11 Suppl Nurse Ed):31-45. PubMed ID: 19856578
[TBL] [Abstract][Full Text] [Related]
34. Graft-vs-host disease following allogeneic hematopoietic cell transplantation.
Pidala J
Cancer Control; 2011 Oct; 18(4):268-76. PubMed ID: 21976245
[TBL] [Abstract][Full Text] [Related]
35. TAK1 inhibition ameliorates survival from graft-versus-host disease in an allogeneic murine marrow transplantation model.
Kobayashi A; Kobayashi S; Miyai K; Osawa Y; Horiuchi T; Kato S; Maekawa T; Yamamura T; Watanabe J; Sato K; Tsuda H; Kimura F
Int J Hematol; 2018 Feb; 107(2):222-229. PubMed ID: 29027124
[TBL] [Abstract][Full Text] [Related]
36. Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokines.
Budde H; Papert S; Maas JH; Reichardt HM; Wulf G; Hasenkamp J; Riggert J; Legler TJ
Ann Hematol; 2017 Jul; 96(7):1127-1133. PubMed ID: 28447161
[TBL] [Abstract][Full Text] [Related]
37. Memory T cells: A helpful guard for allogeneic hematopoietic stem cell transplantation without causing graft-versus-host disease.
Huang W; Chao NJ
Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):211-219. PubMed ID: 28636890
[TBL] [Abstract][Full Text] [Related]
38. [Reconstitution kinetics of dendritic cells following allogeneic hematopoietic stem cell transplantation].
Fu HX; Zhang XH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):222-6. PubMed ID: 18315936
[TBL] [Abstract][Full Text] [Related]
39. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
40. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
